VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2020 | UVEA-IXA: ixazomib-based therapy in R/R myeloma treated via European early access program

Heinz Ludwig, MD, Wilhelminen Cancer Research Institute, Wilhelminenspital, Vienna, Austria, outlines the ‘use via early access to ixazomib’ (uvea-ixa) study which investigated ixazomib-based therapy in relapsed/refractory multiple myeloma (MM) patients treated via an early access program in Europe. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter